Literature DB >> 3090139

Induction of immune tolerance by administration of monoclonal antibody to L3T4.

N L Gutstein, W E Seaman, J H Scott, D Wofsy.   

Abstract

Immune responses can be profoundly altered in mice by treatment with monoclonal antibodies (MAb) to L3T4, the mouse homologue for the CD4 antigen in humans. Treatment of mice with anti-L3T4 blocks both primary and secondary immune responses, delays allograft rejection, and retards autoimmunity. To determine whether anti-L3T4 could also be used to induce tolerance, we investigated the effect of treatment with rat MAb to L3T4 on the immune response to two other rat MAb: MAb to chicken egg ovalbumin (OVA) and MAb to T200, an antigen expressed on all mouse mononuclear blood cells. Treatment with anti-L3T4 prevented the primary humoral response to both of these MAb. Moreover, the anti-L3T4 MAb induced tolerance to itself, and it induced tolerance to the anti-OVA MAb when the two MAb were given concurrently. However, anti-L3T4 did not induce tolerance to the anti-T200 MAb when these MAb were given concurrently. These findings indicate that treatment with MAb to L3T4 may provide a new method for inducing tolerance to some, but not all, antigens. Because L3T4 in mice is homologous to CD4 in humans, our findings suggest that it may be possible to use anti-CD4 to induce tolerance to specific xenogeneic MAb, thereby facilitating their use as therapeutic agents in people.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090139

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Regulation of immunity by anti-T-cell antibodies.

Authors:  D Wofsy
Journal:  West J Med       Date:  1990-09

Review 2.  Tolerance: an overview and perspectives.

Authors:  Herman Waldmann
Journal:  Nat Rev Nephrol       Date:  2010-08-17       Impact factor: 28.314

3.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

5.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

6.  Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response.

Authors:  D Moskophidis; S P Cobbold; H Waldmann; F Lehmann-Grube
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies.

Authors:  G G Oliveira; P R Hutchings; I M Roitt; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.

Authors:  J D Isaacs; N Burrows; M Wing; M T Keogan; P R Rebello; R A Watts; R J Pye; P Norris; B L Hazelman; G Hale; H Waldmann
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 10.  Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.

Authors:  Samuele E Burastero; Mariangela Figini; Barbara Frigerio; Paolo Lusso; Luca Mollica; Lucia Lopalco
Journal:  J Transl Med       Date:  2009-11-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.